Introduction {#Sec1}
============

It is widely accepted that the deregulation of cellular homeostasis observed in cancer cells may be a consequence of the aberrations in the epigenetic information besides genetic mutations (Kulis and Esteller [@CR22]). Epigenetic mechanisms are responsible for the regulation of gene expression and their frequent changes in carcinogenesis are especially attractive for investigation because of their potential applicability in both tumor diagnostics and therapy. The hypermethylation of CpG islands in the promoter regions of tumor suppressor genes, which leads to their silencing, can be found at all stages of carcinogenesis. The profile of DNA methylation changes is claimed to be relatively specific for tumor (sub)type, which makes it a promising biomarker for disease detection and stratification. Evidence shows that it may be also used for both prognostic and predictive purposes (Paluszczak and Baer-Dubowska [@CR30]).

Central nervous system (CNS) cancers are usually highly malignant, chemo- and radio-resistant, and difficult to cure by surgical resection. The most common brain cancers of adults are gliomas, with glioblastoma (GBM) being the most common and most aggressive. Despite advances in neuro-imaging, neurosurgery, and chemotherapy, the survival time of GBM patients very rarely exceeds 2 years, and the median survival time is only about 12 months (Johnson et al. [@CR21]). The observation that the hypermethylation of *MGMT* may be a good predictive factor of the response of CNS cancer patients to alkylating anti-cancer drugs, especially temozolomide, led to attempts of clinical application of epigenetic diagnostics (Esteller et al. [@CR7]; Hegi et al. [@CR17], [@CR18]). The specificity of the predictive testing of *MGMT* methylation is, however, sometimes questioned, since this drug resistance phenotype may also depend on other molecular changes (McEllin et al. [@CR26]; Zhang et al. [@CR44]). The elaboration of a diagnostic gene panel including *MGMT* could potentially improve clinical validity. Apart from *MGMT*, DNA methylation changes in CNS tumors also affect other genes, especially tumor suppressors, such as *RASSF1A*, *p15INK4B*, or *p14ARF* (Lorente et al. [@CR25]; Mulholland et al. [@CR28]; Riemenschneider et al. [@CR34]; Wolter et al. [@CR42]). Their silencing is one of the mechanisms which finally lead to uncontrolled cell proliferation and evading apoptosis and, subsequently, to the acquisition of an aggressive phenotype. Hypermethylation of those genes was found to be involved not only in the carcinogenesis of the CNS tissues, but also breast (Buyru et al. [@CR3]; Fiegl et al. [@CR8]; Sharma et al. [@CR35]) or lung (Furonaka et al. [@CR12]; Ramirez et al. [@CR33]) and in malignant melanoma (Freedberg et al. [@CR11]; Tellez et al. [@CR37]). Such solid tumors often metastasize to the brain and it is thought that DNA methylation changes may be responsible for the acquisition of cerebral metastatic potential by those cells. Metastases are the most common tumors of the CNS, and lung carcinoma, melanoma, and breast carcinoma are the primary tumors most frequently involved in brain invasion (Gavrilovic and Posner [@CR14]; Gonzalez-Gomez et al. [@CR15]).

Because of the limitations in the accessibility of CNS tumor tissue for diagnostic purposes, other sources of tumor-derived DNA are in high demand. There is evidence that significantly higher levels of free-circulating DNA are present in the serum of solid tumor patients and it is believed that most of this DNA is derived from tumor cells (Fiegl et al. [@CR8]; Fleischhacker and Schmidt [@CR9]). Although CNS tumors may shed free DNA into the extracellular space at the same rate as systematic tumors, several anatomic and physiologic differences make it uncertain as to how much of this DNA may reach systematic circulation. Primary CNS tumors are confined to the cranial vault, where their extracellular space drains largely into the cerebrospinal fluid (CSF), which, following circulation, will eventually clear into the bloodstream. This sink effect of the CSF may substantially dilute the amount of detectable circulating nucleic acids in the blood samples of patients with CNS tumors (Lavon et al. [@CR24]).

So far, only a few studies have evaluated the levels of free-circulating DNA in CNS neoplasms in the context of the detection of gene promoter methylation (Lavon et al. [@CR24]; Wakabayashi et al. [@CR39]; Weaver et al. [@CR41]). Moreover, different protocols for sample collection and circulating DNA assessment were used in these studies, and a limited number of gene promoters was evaluated. Since the quantity of free-circulating DNA found in serum is low, the use of an appropriate method of DNA extraction is of high importance. As a result of the comparison of different methods of isolation of DNA from the serum of colorectal cancer patients, Fong et al. ([@CR10]) proposed that the sodium iodide protocol is the best option.

In this study, we compared the profile of aberrant methylation of *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF* genes in serum free-circulating DNA and corresponding tumor tissue in a group of CNS cancer patients. *MGMT*, the O^6^-methylguanine-DNA methyltransferase gene, is located at chromosome 10q26 and encodes a DNA repair enzyme that can abrogate the effects of alkylating chemotherapy, such as temozolomide. *RASSF1A* encodes a Ras association domain family member 1 protein, which interacts with DNA repair protein XPA and is frequently inactivated by hypermethylation of its promoter region. *p15INK4B*, cyclin-dependent kinase inhibitor 2B gene, and *p14ARF* (alternative transcript of the INK4b-ARF-INK4a locus located on human chromosome 9p21) are tumor suppressors inactivated in a variety of cancers. *p15INK4B* encodes a cyclin-dependent kinase inhibitor, whereas *p14ARF* functions as a stabilizer of p53. Those genes were selected based on available information concerning the role of their methylation in brain carcinogenesis. In the majority of cases, gene methylation profiles detected in free-circulating DNA reflected methylation profiles observed in tumor tissue samples.

Patients and methods {#Sec2}
====================

Patient demographics {#Sec3}
--------------------

Thirty-three newly diagnosed, previously untreated patients under the care of the Department of Neurosurgery and Neurotraumatology at the Poznań University of Medical Sciences were included in the study (18 men and 15 women). Seventeen patients were diagnosed with brain tumor of glial origin: primary or recurrent glioblastoma (7 patients), astrocytoma (8), or gliosarcoma (2). The remaining 16 patients suffered from either meningiomas (6 patients) or metastatic CNS cancer (10). The median age was 57.9 years (ranging from 35 to 75 years). Serum samples were obtained from all patients, while paired tumor tissue specimens were available for 16 patients. The clinical characteristics of the study group, including sex, age, and clinical diagnoses, are presented in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. The research was approved by the local Ethics Committee at the Poznań University of Medical Sciences.Table 1The results of *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF* methylation analysis performed in DNA isolated from serum or tumor of glioma patientsNo.PatientDiagnosisWHOAge (years)SexSerum *MGMT*Serum *RASSF1A*Serum *p15INK4B*Serum *p14ARF*Tumor *MGMT*Tumor *RASSF1A*Tumor *p15INK4B*Tumor *p14ARF*1P1Recurrent gliosarcomaIV66mUUUU2P2GBMIV60fUUUM3P3AAIII71fUMUU4P4AAIII62mMMUU5P5AAIII49fUMUU6P6Recurrent GBM, partly AAIV56mMMUU7P7GBMIV49mUUMM8P8AAIII67fUUMM9P9AAIII45mUUUMUUUM10P10GBMIV50mUMUMUMUM11P11Recurrent GBMIV64mMMUMMMUM12P12AAIII58mUUUUUMUU13P13GliosarcomaIV75fUUUUMUUU14P14Fibrillary AII38fUMUUUMUU15P15Recurrent GBMIV51fUUUUUMUU16P16Fibrillary A, partly protoplasmicII51mUMUMUMMU17P17Recurrent GBMIV61fUUUUUMUMΣ M3/178/172/177/172/97/91/94/9% M17.65 %47.06 %11.76 %41.18 %22.22 %77.78 %11.11 %44.44 %*M* and *U* stand for methylated and unmethylated promoter status, respectively, *P* patient, *GBM* glioblastoma, *AA* anaplastic astrocytoma, *Fibrillary A* fibrillary astrocytoma, *f* female, *m* male, *WHO* World Health Organization (WHO) grading of brain cancersTable 2The results of *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF* methylation analysis in DNA isolated from serum or tumor of patients with non-glial tumors \[meningiomas and metastatic central nervous system (CNS) cancers\]No.PatientDiagnosisWHOAge (years)SexSerum *MGMT*Serum *RASSF1A*Serum *p15INK4B*Serum *p14ARF*Tumor *MGMT*Tumor *RASSF1A*Tumor *p15INK4B*Tumor *p14ARF*1P18MC - lungn/a56fUUUU2P19Atypical meningiomaII58mUUUM3P20MC - lungn/a74mUUUM4P21Recurrent, clear cell, angiomatous meningiomaII53fUMUU5P22Fibrous meningiomaI71fUUUU6P23MC - breastn/a58fUMMM7P24Meningothelial meningioma, partly microcysticI62mUUUU8P25Meningothelial meningiomaI64fMMMU9P26MC - malignant melanoman/a62mUMUU10P27MC - breastn/a38fUUMUUUUU11P28MC - lungn/a54mUUUUUUUM12P29MC - lungn/a65mUUUMUUUM13P30MC - lungn/a61mUUMUUUUU14P31MC - lungn/a54mUUUUUMUU15P32MC - lungn/a72mUMUUUUUU16P33Fibrous meningioman/a35fUUUUUUUMΣ M1/165/164/164/160/71/70/73/7% M6.25 %31.25 %25.00 %25.00 %0.00 %14.29 %0.00 %42.86 %*M* and *U* stand for methylated and unmethylated promoter status, respectively, *P* patient, *MC -- lung* metastatic brain cancer originating in the lungs, *f* female, *m* male, *WHO* WHO grading of brain cancers, *n/a* not available

DNA isolation {#Sec4}
-------------

DNA from the tumor tissue was isolated using the GeneMATRIX Tissue DNA Purification Kit (EURx, Gdańsk, Poland), according to the manufacturer's protocol. Circulating tumor-derived DNA was isolated from serum using the sodium iodide/glycogen method. Briefly, enzyme reaction solution, containing 1.43 % SDS, 7.15 mM EDTA, 14.3 mM Tris, (pH 8.0), and Proteinase K, was added to serum and the mixture was incubated at 56 °C for 2 h. Subsequently, glycogen solution (Fermentas, Burlington, Canada) was added, followed by the addition of 9M sodium iodide and an equal volume of isopropanol. After a 15-min incubation, the sample was centrifuged (10,000 × g for 20 min) and the pellet was washed with 45 % isopropanol and centrifuged. Washing was repeated with 75 % ethanol. After the final centrifugation, the pellet was dried and dissolved in Tris-EDTA buffer. The concentration and quality of DNA samples was assessed using a NanoDrop spectrophotometer. The mean recovery of total DNA from 3 ml of serum was 8.62 μg (mean concentration of 43.1 ng/μl, with an elution volume of 200 μl).

DNA methylation analysis {#Sec5}
------------------------

The assessment of the methylation status of *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF* was performed using methylation-specific polymerase chain reaction (PCR) (Herman et al. [@CR19]). Completely methylated control DNA (CpG Methylated HeLa Genomic DNA, New England Biolabs, UK) and completely unmethylated control DNA (EpiTect Control DNA, Qiagen, Germany) served as positive and negative controls, respectively. Additionally, leukocytes from healthy volunteers as well as a DNA sample extracted from a brain fragment of a patient with brain hematoma served as normal control samples for DNA methylation analysis. They showed no detectable hypermethylation of the genes analyzed.

Bisulfite modification of 500 ng DNA was performed using the EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA), following manufacturer's instructions. Methylation-specific PCR assay was carried out in a MyCycler Thermal Cycler (Bio-Rad). Primer oligonucleotides were obtained from Oligo.pl (Warsaw, Poland). Primer sequences for all the analyzed genes and reaction conditions were chosen based on previously published protocols (Dong et al. [@CR6]; Herman et al. [@CR19]; Pizzi et al. [@CR31]; Table [3](#Tab3){ref-type="table"}). All primer pairs were targeted towards gene promoter-associated CpG islands. PCR reactions were carried out in a volume of 18 μl using FastStart Taq DNA Polymerase (Roche, Germany) as follows: after an initial step of heat denaturation at 94 °C for 4 min, 38 cycles of 94 °C for 30 s, appropriate annealing temperature for 30 s, and 72 °C for 45 s were carried out. Final elongation was carried out at 72 °C for 7 min. PCR products were separated by 2 % agarose gel electrophoresis in the presence of ethidium bromide and visualized under UV illumination.Table 3Primers used in methylation-specific polymerase chain reaction (PCR) assaysGenePrimerSequenceAmplicon sizeAnnealing temperatureReference*MGMT*MFTTTCGACGTTCGTAGGTTTTCGC81 bp60 °CDong et al. ([@CR6])MRGCACTCTTCCGAAAACGAAACGUFTTTGTGTTTTGATGTTTGTAGGTTTTTGT93 bpURAACTCCACACTCTTCCAAAAACAAAACA*RASSF1A*MFGTGTTAACGCGTTGCGTATC94 bp60 °CPizzi et al. ([@CR31])MRAACCCCGCGAACTAAAAACGAUFTTTGGTTGGAGTGTGTTAATGTG108 bpURCAAACCCCACAAACTAAAAACAA*p15INK4B*MFGCGTTCGTATTTTGCGGTT148 bp60 °CHerman et al. ([@CR19])MRCGTACAATAACCGAACGACCGAUFTGTGATGTGTTTGTATTTTGTGGTT154 bpURCCATACAATAACCAAACAACCAA*p14ARF*MFGTGTTAAAGGGCGGCGTAGC122 bp60 °CDong et al. ([@CR6])MRAAAACCCTCACTCGCGACGAUFTTTTTGGTGTTAAAGGGTGGTGTAGT132 bp58 °CURCACAAAAACCCTCACTCACAACAA

Statistical analysis {#Sec6}
--------------------

Data were analyzed using Fisher's exact test, with *p* ≤ 0.05 being considered as statistically significant.

Results {#Sec7}
=======

The applied protocol of DNA isolation from serum yielded an amount sufficient for the assessment of gene hypermethylation in CNS cancer patients. Methylation of at least one promoter was demonstrated in 12 out of 17 (70.58 %) serum samples from the glial tumor group, where 5 patients had one, 6 patients had two, and 1 patient had three promoters methylated, respectively (Table [1](#Tab1){ref-type="table"}). In this group, *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF* were methylated in 3/17 (17.65 %), 8/17 (47.06 %), 2/17 (11.76 %), and 7/17 (41.18 %) cases, respectively. At least one promoter was methylated in the serum of 7 out of 10 metastatic CNS tumor patients and 3 out of 6 meningothelial tumor patients (Table [2](#Tab2){ref-type="table"}). *MGMT* was methylated in the circulating tumor-derived DNA from only one meningioma patient, *RASSF1A* methylation was found in two meningiomas and three metastatic tumors, and the methylation of both *p15INK4B* and *p14ARF* was detected in one meningioma and three metastatic tumors, respectively.

Apart from serum, samples of the corresponding tumor tissue were available for 9 patients with glial and 7 patients with non-glial tumors. The comparative analysis of DNA methylation between these two sample sources is presented in Table [4](#Tab4){ref-type="table"}. The concordance of gene hypermethylation results was relatively high for all the analyzed genes. Among all the patients, 13 discordant results (20.3 %) were observed. These were mostly false-negative cases (in respect to serum analysis). Interestingly, false-positive results were observed mostly (75 %) in the group of metastatic cancers.Table 4Tumor--serum comparative analysis of gene methylationNo.Patient*MGMTRASSF1Ap15INK4Bp14ARF*TumorSerumConcordanceTumorSerumConcordanceTumorSerumConcordanceTumorSerumConcordanceGlial tumors1P9UUyesUUyesUUyesMMyes2P10UUyesMMyesUUyesMMyes3P11MMyesMMyesUUyesMMyes4P12UUyesMUFNUUyesUUyes5P13MUFNUUyesUUyesUUyes6P14UUyesMMyesUUyesUUyes7P15UUyesMUFNUUyesUUyes8P16UUyesMMyesMUFNUMFP9P17UUyesMUFNUUyesMUFNΣ M2/91/98/97/94/96/91/90/98/94/94/97/9% M22.22 %11.11 %88.89 %77.78 %44.44 %66.67 %11.11 %0.00 %88.89 %44.44 %44.44 %77.78 %Other CNS tumors10P27UUyesUUyesUMFPUUyes11P28UUyesUUyesUUyesMUFN12P29UUyesUUyesUUyesMMyes13P30UUyesUUyesUMFPUUyes14P31UUyesMUFNUUyesUUyes15P32UUyesUMFPUUyesUUyes16P33UUyesUUyesUUyesMUFNΣ M0/70/77/71/71/75/70/72/75/73/71/75/7% M0.00 %0.00 %100.00 %14.29 %14.29 %71.43 %0.00 %28.57 %71.43 %42.86 %14.29 %71.43 %Both groups togetherΣ M2/161/1615/168/165/1611/161/162/1613/167/165/1612/16% M12.50 %6.25 %93.75 %50.00 %31.25 %68.75 %6.25 %12.50 %81.25 %43.75 %31.25 %75.00 %Global concordance51/64 (79.69 %)*M* and *U* stand for methylated and unmethylated promoter status, respectively, *P* patient, *FN* false-negative result, *FP* false-positive result

No statistical differences in the frequency of gene hypermethylation between glial and non-glial cancer patients were found when it comes to neither serum nor tumor tissue, except for *RASSF1A*. In this case, gene promoter methylation was significantly more frequent in the samples of glial tumors in comparison to metastatic CNS cancers (*p* = 0.0406) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Comparison of *RASSF1A* methylation detected in the tumor tissue of glial versus metastatic central nervous system (CNS) tumors

Discussion {#Sec8}
==========

In the past few years, much data have been gathered showing that cancers of different origins release DNA into the bloodstream (Fiegl et al. [@CR8]; Fleischhacker and Schmidt [@CR9]). Even though the data concerning solid tumors, such as lung, colon, or breast, showed the presence of tumor-derived DNA in the blood, a limited number referred to CNS cancers. The classical view of the brain as an isolated environment, with the blood--brain barrier being impenetrable to large molecules such as DNA, suggested possible obstacles in finding methylation biomarkers in the blood of those patients. However, a recent verification of this hypothesis showed that tumor-derived DNA is present in the serum of glioma patients and that its analysis is eligible for biomarker purposes (Lavon et al. [@CR24]; Wakabayashi et al. [@CR39]; Weaver et al. [@CR41]). Our observations confirm the findings that circulating tumor-derived DNA is present in the serum of CNS cancer patients. Additionally, we verified the utility of the sodium iodide method in yielding DNA of appropriate quantity and quality for further methylation detection, as suggested previously in the case of colorectal tumors (Fong et al. [@CR10]). Because of poor treatment outcomes in the group of brain cancer patients, laboratory tests based on methylation analysis of tumor-derived free-circulating DNA may be potentially useful in patient prognosis and the choice of the best suited therapy regimen (Weaver et al. [@CR41]).

In the present study, we analyzed the promoter methylation of *MGMT*, *RASSF1A*, *p15INK4B*, and *p14ARF*. It has been proven that these genes play a role in the pathogenesis of CNS cancers, where promoter hypermethylation is one of the mechanisms of their silencing. For example, it was suggested that *p14ARF* hypermethylation and *MGMT* hypermethylation constitute distinct molecular pathways of astrocytoma progression, and it is hypothesized that these pathways could differ in biological behavior and clinical outcome (Watanabe et al. [@CR40]). From the diagnostic point of view, *MGMT* hypermethylation is an important predictive marker of good response to alkylating chemotherapy in GBM. Interestingly, some reports support the thesis that serum-based *MGMT* methylation analysis offers a promising alternative to a tumor-based approach (Balańa et al. [@CR1]). Although the assessment of *MGMT* hypermethylation is a valuable marker in the prediction of the response of GBM patients to temozolomide treatment (Silber et al. [@CR36]), some studies indicate that its diagnostic performance is not satisfactory and other methylation-based markers are proposed, e.g., *PTEN* or *hMLH1* (McEllin et al. [@CR26]; Plumb et al. [@CR32]). Therefore, further studies aiming at finding new relevant markers are necessary in order to improve the effectiveness of therapy of CNS cancer patients.

Several studies showed that serum might be a source for circulating DNA. In contrast to plasma, serum contains significantly higher amounts of DNA, with a low level of contaminating extraneous DNA released from leukocytes (Umetani et al. [@CR38]). Thus, we first analyzed the methylation of the selected panel of genes in serum samples obtained from patients with CNS cancers of glial or non-glial (mostly metastatic) origin. Overall, the rate of hypermethylation of the tested genes, besides *p15INK4B*, was higher in the group of patients with tumors of glial origin. We report frequent methylation of *RASSF1A* in circulating tumor-derived DNA found in the serum of patients with both primary as well as metastatic CNS tumors. This finding is in agreement with published data, which show the involvement of *RASSF1A* epigenetic silencing in CNS carcinogenesis (Lorente et al. [@CR25]). When it comes to serum *RASSF1A* methylation-positive cases of brain tumor patients, similar results were obtained in the study of Dammann et al. ([@CR5]). The second gene which also showed frequent hypermethylation in the studied patient group was *p14ARF*, and recent data suggest that methylation in the promoter region of *p14ARF* may be used as a biomarker for the diagnosis of gliomas (He et al. [@CR16]). We observed an intermediate frequency of *MGMT* methylation in the serum of patients with glial tumors (17.65 %), while it was low (6.25 %) in the serum of non-glial tumor patients. The percentage of CNS cancer cases where methylated *MGMT* was detected in the serum ranged from 20 to 50 % in other reports (Lavon et al. [@CR24]; Weaver et al. [@CR41]). Finally, *p15INK4B* was observed to be methylated with moderate frequency in the serum of cancers of both glial origin (11.76 %) and in the group consisting of non-glial tumor patients (25 %).

Of 33 serum samples under analysis, 16 had paired frozen tissues available for assessment. The frequencies of gene hypermethylation in tumor samples were similar to those detected in serum with some exceptions, resulting probably from the different number of patients in the groups. The corresponding values were in agreement with previously published data concerning the methylation of *MGMT* (Cecener et al. [@CR4]; Mellai et al. [@CR27]), *RASSF1A* (Dammann et al. [@CR5]; Gao et al. [@CR13]; Horiguchi et al. [@CR20]), *p14ARF* (He et al. [@CR16]; Nakamura et al. [@CR29]), or *p15INK4B* (Watanabe et al. [@CR40]; Yin et al. [@CR43]) in CNS tumor cells, especially when taking into account the glial tumor group. Moreover, for the first time, we propose that *RASSF1A* hypermethylation may differentiate primary from metastatic CNS cancers.

The comparison of the results obtained for paired serum and tumor samples allowed the conclusion that the global concordance of results between these two sample sources is fairly high (Table [4](#Tab4){ref-type="table"}). It is generally believed that serum-based marker analysis shows higher specificity (which is reflected by the rate of false-positive results) than sensitivity (reflected by the rate of false-negative results) of detection (Laird [@CR23]). This assumption is confirmed also in our studies. Thus, in general, biomarker methylation was more frequently found in DNA from tumor than from serum, similar to that reported by others (Board et al. [@CR2]). Also, in the studies of Weaver et al. ([@CR41]) and Lavon et al. ([@CR24]), 40 to 50 % of patients were characterized by the hypermethylation of *MGMT* in tumor samples, while only half of them showed paired *MGMT* methylation in free-circulating serum DNA. This can possibly be explained by the fragmentation of circulating tumor-derived DNA. Interestingly, most cases of false-positive gene methylation results were detected in the group of metastatic CNS cancer patients, while false-negative results were more frequently found in glial tumor patients. The possible explanation of this phenomenon is that the methylation markers detected in the serum of metastatic tumor patients can come from DNA originating in the primary tumor site and the metastatic cells creating the CNS tumor may not fully reflect the DNA methylation profile characterizing cells in the primary tumor tissue.

Conclusions {#Sec9}
===========

In conclusion, our study seems to confirm the previous findings (Lavon et al. [@CR24]; Wakabayashi et al. [@CR39]; Weaver et al. [@CR41]) that the blood--brain barrier does not interfere significantly with the leakage of tumor-specific DNA into the global circulation, which makes the detection of methylation biomarkers in the serum of CNS cancer patients possible. Gene methylation in the tumor was accompanied by its methylation in paired serum samples in only half of positive cases. The sensitivity of the assay is, therefore, not satisfactory, and further research is necessary in order to establish a marker panel with optimal clinical performance. The results, however, illustrate that the circulating tumor-derived DNA harbors the methylation markers found in the originating tumor tissue and is eligible for clinical biomarker assessment. Additionally, an important novel finding is that metastatic CNS cancers are characterized by a different spectrum of epigenetic changes than primary glial tumors, with *RASSF1A* hypermethylation differentiating between these two groups. Our work further supports the search for epigenetic CNS tumor markers.
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